Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gene therapy with VEGF].

L Maillard1, P Peycher, O Fichaux

  • 1Laboratoire de Biotechnologie et Génétique expérimentale, CHU Trousseau, Tours. luc.maillard@med.univ-tours.fr

Presse Medicale (Paris, France : 1983)
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-lasting improvement of memory after targeted cognitive remediation in temporal epilepsy: A randomized control study.

Revue neurologique·2025
Same author

Visual phenomena and anatomo-electro-clinical correlations in occipital lobe seizures.

Revue neurologique·2022
Same author

Epilepsy surgery for drug-resistant temporal lobe epilepsy in over-50 year-olds: Seizure outcome, surgical complications and neuropsychological outcome.

Neuro-Chirurgie·2022
Same author

Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.

The British journal of surgery·2021
Same author

Long-term cognitive outcomes in patient with epilepsy.

Revue neurologique·2020
Same author

Attention disorders in adults with epilepsy. Determinants and therapeutic strategies.

Revue neurologique·2019
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

New gene therapy using vascular endothelial growth factor (VEGF) shows promise for treating severe limb ischemia by stimulating new blood vessel growth. This angiogenesis therapy offers a potential alternative to amputation.

Area of Science:

  • Cardiovascular Research
  • Gene Therapy
  • Regenerative Medicine

Background:

  • Atherosclerosis leads to lower limb ischemia, a major cause of mortality and amputation.
  • Current treatments for severe limb ischemia are limited, necessitating new therapeutic strategies.
  • Angiogenesis therapy, stimulating new blood vessel formation, is a promising approach.

Purpose of the Study:

  • To explore the potential of vascular endothelial growth factor (VEGF) as a therapeutic agent for angiogenesis.
  • To evaluate different administration routes for VEGF gene therapy.
  • To assess the feasibility and efficacy of VEGF in promoting collateral circulation.

Main Methods:

  • Delivery of DNA fragments encoding VEGF via catheter-based hydrogel balloons to arterial walls.

Related Experiment Videos

  • Intramuscular administration of VEGF gene therapy to leverage muscle cell protein synthesis.
  • Preclinical studies demonstrating VEGF's ability to stimulate collateral circulation.

    • Main Results:

    • Preclinical data supports VEGF's role in stimulating collateral circulation.
    • Intramuscular VEGF gene therapy utilizes peripheral muscle cells for protein production.
    • Early clinical observations suggest feasibility and potential benefit in limited patient cohorts.

    Conclusions:

    • Angiogenic cytokines like VEGF show potential for treating ischemic conditions.
    • Intramyocardial VEGF injection is feasible, with ongoing larger trials planned.
    • Further research is needed to address remaining questions despite promising preclinical data.